We are live on ! Find out more
OFM

Omega Fund Management Portfolio holdings

AUM $163M
1-Year Est. Return 107.06%
This Fund
S&P 500
This Quarter Est. Return
+26.05%
1 Year Est. Return
+107.06%
3 Year Est. Return
+111.75%
5 Year Est. Return
+84.24%
10 Year Est. Return
+495.59%
AUM
$154M
AUM Growth
+$30.6M
Cap. Flow
+$10.5M
Cap. Flow %
6.85%
Top 10 Hldgs %
99.51%
Holding
12
New
1
Increased
–
Reduced
2
Closed
1

Top Buys

Rank Stock Value
1
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
+$12.3M

Top Sells

Rank Stock Value
1
EDIT icon
Editas Medicine
EDIT
+$1.07M
2
CDTX
Cidara Therapeutics
CDTX
+$440K
3
KYNB
Kyntra Bio
KYNB
+$236K

Sector Composition

Rank Sector Weight
1 Healthcare 81.77%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRTK
1
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$50.1M 32.54%
2,600,410
– –
JUNO
2
DELISTED
Juno Therapeutics, Inc.
JUNO
$27.3M 17.73%
1,229,512
– –
KYNB
3
Kyntra Bio
KYNB
$28.5M
$20M 13.02%
32,500
-387
-1% -$236K
EGLT
4
DELISTED
Egalet Corporation
EGLT
$14.7M 9.58%
2,889,926
– –
NBRV
5
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$13.8M 8.94%
4,584
– –
JNCE
6
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$12.7M 8.29%
+579,650
New +$12.3M
EPIX
7
DELISTED
ESSA Pharma
EPIX
$5.29M 3.44%
84,848
– –
PVLA
8
Palvella Therapeutics
PVLA
$1.98B
$4.41M 2.87%
21,217
– –
CDTX
9
DELISTED
Cidara Therapeutics
CDTX
$3.47M 2.26%
22,248
-2,505
-10% -$440K
CBAY
10
DELISTED
Cymabay Therapeutics
CBAY
$1.3M 0.84%
301,477
– –
DRNA
11
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$760K 0.49%
223,457
– –
EDIT icon
12
Editas Medicine
EDIT
$399M
– –
-66,162
Closed -$1.07M

Similar funds

HCCM
Hudson Canyon Capital Management New York $163M AUM 33.71% 1-Year Est. Return
PBO
Peoples Bank (Ohio) Marietta, Ohio $163M AUM 18.72% 1-Year Est. Return
PCR
Potrero Capital Research San Francisco, California $163M AUM 79.07% 1-Year Est. Return
BCM
Basso Capital Management Stamford, Connecticut $163M AUM 21.95% 1-Year Est. Return
IVGAI
Index Venture Growth Associates IV St. Helier, Jersey $163M AUM 54.88% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return
TCGDR
TB Capital Gestao de Recursos Rio De Janeiro $163M AUM 20.86% 1-Year Est. Return
IPWA
International Private Wealth Advisors San Diego, California $163M AUM 16.99% 1-Year Est. Return

Omega Fund Management's Q1 2017 Portfolio in Review

As of Q1 2017, Omega Fund Management held 12 positions worth $154M, up 25% from $123M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Omega Fund Management deployed $10.5M of net new capital in Q1 2017, opening 1 new position. Its largest new stake was Jounce Therapeutics, Inc. Common Stock: 579,650 shares worth $12.7M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 81% a quarter earlier.

On the sell side, the largest reduction was Cidara Therapeutics, an estimated $440K trimmed.

  • Omega Fund Management's largest Q1 2017 buy was Jounce Therapeutics, Inc. Common Stock: 579,650 shares worth $12.7M.
  • Omega Fund Management's biggest Q1 2017 reduction was Cidara Therapeutics, cutting an estimated $440K.
  • Omega Fund Management fully exited Editas Medicine in Q1 2017, selling an estimated $1.07M.
  • Omega Fund Management's ten largest holdings make up 100% of its $154M portfolio in Q1 2017.
  • Omega Fund Management opened 1 new position and closed 1 in Q1 2017.
  • Omega Fund Management's portfolio value rose 25% quarter-over-quarter to $154M.

Based on Omega Fund Management's 13F filing for Q1 2017, filed 9 May 2017.